WallStSmart

Intel Corporation (INTC)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intel Corporation generates 1569% more annual revenue ($53.76B vs $3.22B). WST leads profitability with a 16.9% profit margin vs -5.9%. INTC appears more attractively valued with a PEG of 1.36. WST earns a higher WallStSmart Score of 67/100 (B-).

INTC

Avoid

33

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 4.3Quality: 7.0
Piotroski: 5/9Altman Z: 1.69

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INTCSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$35.50

Current Price

$124.92

$89.42 premium

UndervaluedFair: $35.50Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INTC1 strengths · Avg: 10.0/10
Market CapQuality
$627.85B10/10

Mega-cap, among the largest globally

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

INTC4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-71.7%2/10

Earnings declined 71.7%

Free Cash FlowQuality
$-2.54B2/10

Negative free cash flow — burning cash

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : INTC

The strongest argument for INTC centers on Market Cap. PEG of 1.36 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : INTC

The primary concerns for INTC are Altman Z-Score, Return on Equity, EPS Growth.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

INTC profiles as a turnaround stock while WST is a growth play — different risk/reward profiles.

INTC carries more volatility with a beta of 2.19 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 33/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intel Corporation

TECHNOLOGY · SEMICONDUCTORS · USA

Intel Corporation is an American multinational corporation and technology company headquartered in Santa Clara, California, in Silicon Valley. It is the world's largest semiconductor chip manufacturer by revenue, and is the developer of the x86 series of microprocessors, the processors found in most personal computers (PCs).

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?